Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07088419 | "Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)" | PHASE2 | RECRUITING | 40 | — | — | Jul 23, 2025 | Aug 31, 2026 | May 4, 2026 | 1 | United States |
Microbiologic cure of M. genitalium will be determined at a test of cure visit. Microbiologic cure will be defined as a negative test for M. genitalium in a urine specimen using a nucleic acid amplification test.
| Arm | Type | Description |
|---|---|---|
| Tinidazole | EXPERIMENTAL | Single Arm |
| Name | Type | Description |
|---|---|---|
| Tinidazole | DRUG | 2 grams orally on day one followed by 500mg orally twice daily on days 2-10 |
Inclusion Criteria: * ≥18 years of age * Clinical diagnosis of NGU * Urogenital MG documented by a positive NAAT in the prior 7 days * Fluent in English * Assigned male at birth * Attending the PHSKC SHC * Able to provide informed consent * Able to undergo a test of cure (TOC) 21 days after complet...